Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
about
Trial Watch-Immunostimulation with cytokines in cancer therapyTrial Watch: Radioimmunotherapy for oncological indications.Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody.Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients.Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
P2860
Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@en
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@nl
type
label
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@en
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@nl
prefLabel
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@en
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@nl
P2093
P2860
P356
P1433
P1476
Myeloablative anti-CD20 radioi ...... excellent long-term survival.
@en
P2093
Burkhard Schmidt
Christian Peschel
Christoph von Schilling
Hans-Jürgen Wester
Julia Y Wagner
Kathleen Schwarz
Klemens Scheidhauer
Markus Schwaiger
Susanne Schreiber
Ulrich Keller
P2860
P304
P356
10.18632/ONCOTARGET.1037
P407
P577
2013-06-01T00:00:00Z